ESG Meeting

(Discussion with Investors)

December 13, 2022

Sumitomo Pharma Co., Ltd.

Disclaimer Regarding Forward-looking Statements

  • This material contains forecasts, projections, goals, plans, and other forward-looking statements regarding the Group's financial results and other data. Such forward-looking statements are based on the Company's assumptions, estimates, outlook, and other judgments made in light of information available at the time of preparation of such statements and involve both known and unknown risks and uncertainties.
  • Accordingly, forecasts, plans, goals, and other statements may not be realized as described, and actual financial results, success/failure or progress of development, and other projections may differ materially from those presented herein.
  • Information concerning pharmaceuticals and medical devices (including compounds under development) contained herein is not intended as advertising or as medical advice.
  • Myovant Sciences Ltd. ("Myovant") is listed on the New York Stock Exchange, and the Group beneficially owns approximately 52% of the outstanding shares of Myovant. ORGOVYX® (relugolix), MYFEMBREE®/RYEQO® (relugolix combination tablet) are owned by Myovant. This material contains information about Myovant, which is based on information disclosed by Myovant. For more information on Myovant, please visit https://www.myovant.com.

© Sumitomo Pharma Co., Ltd. All Rights Reserved.

1

Today's Purpose and Agenda

Today's purpose

We will reorganize material issues from the perspective of the degree of their impacts on the value we provide based on our corporate mission. Exchange opinions on "Our capital (strengths/potential)," which is the source of our unique value creation and is important for reorganizing material issues

1. Toward Reorganization of Material Issues

Executive Officer

Naoki Noguchi

2. Panel Discussion on the Company's Capital (strengths/potential), etc.

Panelists:

Representative Director, President and CEO

Hiroshi Nomura

Representative Director, Executive Vice President

Toru Kimura

Member, Board of Directors (Outside)

Saeko Arai

Member, Board of Directors (Outside)

Minoru Usui

Member, Board of Directors (Outside)

Koji Fujimoto

Executive Officer

Naoki Noguchi

Facilitator:

RIDEAL CEO

Mariko Mishiro

© Sumitomo Pharma Co., Ltd. All Rights Reserved.

2

Toward Reorganization of Material Issues

Naoki Noguchi

Executive Officer

© Sumitomo Pharma Co., Ltd. All Rights Reserved.

3

Status of Updates based on Our Past Initiatives and Dialogue with Stakeholders regarding Material Issues

FY2018: Identified material issues

FY2019: Organized material issues items based on dialogue with stakeholders and classified them into the following two categories

  1. Solving issues is important for our sustained growth "Materiality linked to value creation"
  2. Solving issues is essential for our business continuity "Materiality that forms the foundation for business continuity"

FY2020: Set targets (qualitative indicators) for material issues items

FY2021: Verified material issues items based on dialogue with stakeholders and set KPIs (For promoting further dialogue with stakeholders)

FY2022: Updated some of the KPIs set in FY2021

© Sumitomo Pharma Co., Ltd. All Rights Reserved.

4

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Sumitomo Dainippon Pharma Co. Ltd. published this content on 13 December 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 December 2022 02:13:03 UTC.